News | February 28, 2026
Novartis completes $12 billion acquisition of Avidity Biosciences
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
The new patents cover critical advancements in cochlear implant technology
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
